

This listing of claims will replace all prior versions and listings of claims in the application:

-

2. (Canceled)

4. (Previously Presented) The crystalline form of claim 1, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1.

5. (Previously Presented) The crystalline form of claim 1, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 5.2, 7.3, 8.1, 10.1, 10.4, 11.2, 13.2, 15.1, 15.5, 17.3, 21.7, 23.8, and 25.1.


6. (Currently amended) The crystalline form of claim 1, wherein the crystalline form of Compound I has a crystal structure with the following characteristics at 122 K: Space group: ~~P2₁2₁2₁~~ P2₁2₁2₁, Unit cell dimensions: a = 10.227(2) Å, b = 23.942(2) Å and c = 24.240(2) Å, α = 90°, β = 90°, γ = 90°, 2 molecules in the asymmetric unit.

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Currently amended) A crystalline form of Compound I, which compound has the formula




~~The crystalline form of claim 1,~~
wherein the crystalline form of Compound I exhibits one or more of: (i) the X-Ray powder diffractogram shown in Figure 3 as measured using CuK α radiation; (ii) reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.6, 11.5, 12.5, 16.7, 19.3, and 28.1; (iii) the solid state Carbon-13 NMR spectrum shown in Figure 9; or (iv) the NIR reflectance spectrum shown in Figure 12.

11. (Currently amended) The crystalline form of claim ~~[[1]]~~ 10, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.6, 11.5, 12.5, 16.7, 19.3, and 28.1.

12. (Currently amended) The crystalline form of claim ~~[[1]]~~ 10, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 7.5, 8.3, 9.6, 11.5, 11.8, 12.5, 15.9, 16.3, 16.7, 17.2, 18.0, 19.3, 21.0, and 28.1.

13. (Cancelled)

14. (Currently amended) A crystalline form of Compound I, which compound has the formula



~~The crystalline form of claim 1,~~
wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 9.7, 12.1, 16.1, 18.3, 22.1, 22.2, 25.7, and 25.8.

15. (Currently amended) The crystalline form of claim ~~[[1]]~~ 14, wherein the crystalline form of Compound I exhibits reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2-theta angles: 7.3, 8.3, 9.7, 11.1, 11.7, 12.1, 15.6, 16.1, 17.3, 18.3, 20.9, 22.1, 22.2, 25.7, and 25.8.

16. (Cancelled)


17. (Cancelled)

18. (Cancelled)

19. (Previously presented) The crystalline form of claim 1, which is substantially pure.

Claims 20 through 34 are cancelled.

35. (Previously presented) A method for preparing crystalline Compound I, comprising forming crystalline Compound I in a solvent of methanol with 0% to about 8% water, wherein Compound I has the formula



36. (Original) The method of claim 35, comprising crystallizing by precipitation Compound I from the solvent and separating the solvent from the obtained crystalline Compound I.

37. (Previously presented) The method of claim 35, wherein said crystalline Compound I exhibits one or more of the following: (i) the X-Ray powder diffractogram shown in Figure 1 as measured using CuK α radiation; (ii) reflections in the X-Ray powder diffractogram as measured using CuK α radiation at 2- theta angles: 5.2, 10.1, 10.4, 13.2, 15.1, and 25.1; (iii) the solid state Carbon-13 NMR spectrum shown in Figure 7; or (iv) the NIR reflectance spectrum shown in Figure 10.

Claims 38 through 46 are cancelled.

47. (Currently amended) A pharmaceutical composition comprising ~~an effective amount of the~~ crystalline form of Compound I of claim 1 and a pharmaceutically acceptable excipient.

Claims 48-54 are cancelled.

55. (New) The crystalline form of claim 14, wherein the crystalline form of Compound I exhibits the X-Ray powder diffractogram shown in Figure 13 as measured using CuK α radiation.

56. (New) A pharmaceutical composition comprising one or more of: the crystalline form of claim 1, the crystalline form of claim 10, or the crystalline form of claim 14.

57. (New) The pharmaceutical composition of claim 56 further comprising one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.

58. (New) The pharmaceutical composition of claim 56 wherein the composition is a solid dispersion or a solid solution formulation.

59. (New) The pharmaceutical composition of claim 47 wherein the composition is a solid dispersion or solid solution formulation.